Chemistry:Zipalertinib
From HandWiki
Zipalertinib is an investigational new drug that is being evaluated for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, particularly exon 20 insertion mutations.[1][2][3]
References
- ↑ "Zipalertinib - Cullinan Therapeutics". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800056381.
- ↑ "TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations". Molecular Cancer Therapeutics 17 (8): 1648–1658. August 2018. doi:10.1158/1535-7163.MCT-17-1206. PMID 29748209. https://aacr.figshare.com/articles/journal_contribution/Figure_S1_from_TAS6417_A_Novel_EGFR_Inhibitor_Targeting_Exon_20_Insertion_Mutations/22504684/1/files/39964528.pdf.
- ↑ "Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer". International Journal of Molecular Sciences 25 (11): 5917. May 2024. doi:10.3390/ijms25115917. PMID 38892105.
 |  |
